ID   MARK4_HUMAN             Reviewed;         752 AA.
AC   Q96L34; Q8NG37; Q96JG7; Q96SQ2; Q9BYD8;
DT   28-FEB-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   12-OCT-2022, entry version 197.
DE   RecName: Full=MAP/microtubule affinity-regulating kinase 4;
DE            EC=2.7.11.1 {ECO:0000269|PubMed:14594945, ECO:0000269|PubMed:15009667, ECO:0000269|PubMed:23184942};
DE   AltName: Full=MAP/microtubule affinity-regulating kinase-like 1;
GN   Name=MARK4; Synonyms=KIAA1860, MARKL1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=11326310; DOI=10.1038/sj.neo.7900132;
RA   Kato T., Satoh S., Okabe H., Kitahara O., Ono K., Kihara C., Tanaka T.,
RA   Tsunoda T., Yamaoka Y., Nakamura Y., Furukawa Y.;
RT   "Isolation of a novel human gene, MARKL1, homologous to MARK3 and its
RT   involvement in hepatocellular carcinogenesis.";
RL   Neoplasia 3:4-9(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY,
RP   COFACTOR, INTERACTION WITH GAMMA-TUBULIN, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=14594945; DOI=10.1074/jbc.m304528200;
RA   Trinczek B., Brajenovic M., Ebneth A., Drewes G.;
RT   "MARK4 is a novel microtubule-associated proteins/microtubule affinity-
RT   regulating kinase that binds to the cellular microtubule network and to
RT   centrosomes.";
RL   J. Biol. Chem. 279:5915-5923(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, AND CATALYTIC
RP   ACTIVITY.
RX   PubMed=15009667; DOI=10.1046/j.1471-4159.2003.02228.x;
RA   Schneider A., Laage R., von Ahsen O., Fischer A., Rossner M., Scheek S.,
RA   Grunewald S., Kuner R., Weber D., Kruger C., Klaussner B., Gotz B.,
RA   Hiemisch H., Newrzella D., Martin-Villalba A., Bach A., Schwaninger M.;
RT   "Identification of regulated genes during permanent focal cerebral
RT   ischaemia: characterization of the protein kinase 9b5/MARKL1/MARK4.";
RL   J. Neurochem. 88:1114-1126(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RA   Beghini A., Magnani I., Roversi G., Piepoli T., DiTerlizzi S., Pollo B.,
RA   Conti A.M.F., Cowell J.K., Finocchiaro G., Larizza L.;
RT   "Neural progenitor-restricted isoform of MARKL1 gene is upregulated by
RT   19q13 amplification in human glioblastoma.";
RL   Submitted (JUN-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=11347906; DOI=10.1093/dnares/8.2.85;
RA   Nagase T., Nakayama M., Nakajima D., Kikuno R., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XX. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 8:85-95(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Thyroid;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   ACTIVITY REGULATION, PHOSPHORYLATION AT THR-214, AND MUTAGENESIS OF
RP   THR-214.
RX   PubMed=14976552; DOI=10.1038/sj.emboj.7600110;
RA   Lizcano J.M., Goeransson O., Toth R., Deak M., Morrice N.A., Boudeau J.,
RA   Hawley S.A., Udd L., Maekelae T.P., Hardie D.G., Alessi D.R.;
RT   "LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily,
RT   including MARK/PAR-1.";
RL   EMBO J. 23:833-843(2004).
RN   [8]
RP   INTERACTION WITH YWHAQ.
RX   PubMed=16959763; DOI=10.1074/mcp.m600147-mcp200;
RA   Angrand P.O., Segura I., Voelkel P., Ghidelli S., Terry R., Brajenovic M.,
RA   Vintersten K., Klein R., Superti-Furga G., Drewes G., Kuster B.,
RA   Bouwmeester T., Acker-Palmer A.;
RT   "Transgenic mouse proteomics identifies new 14-3-3-associated proteins
RT   involved in cytoskeletal rearrangements and cell signaling.";
RL   Mol. Cell. Proteomics 5:2211-2227(2006).
RN   [9]
RP   UBIQUITINATION, DEUBIQUITINATION BY USP9X, AND INTERACTION WITH USP9X.
RX   PubMed=18254724; DOI=10.1042/bj20080067;
RA   Al-Hakim A.K., Zagorska A., Chapman L., Deak M., Peggie M., Alessi D.R.;
RT   "Control of AMPK-related kinases by USP9X and atypical Lys(29)/Lys(33)-
RT   linked polyubiquitin chains.";
RL   Biochem. J. 411:249-260(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [11]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF THR-214.
RX   PubMed=23184942; DOI=10.1074/jbc.c112.396903;
RA   Li L., Guan K.L.;
RT   "Microtubule-associated protein/microtubule affinity-regulating kinase 4
RT   (MARK4) is a negative regulator of the mammalian target of rapamycin
RT   complex 1 (mTORC1).";
RL   J. Biol. Chem. 288:703-708(2013).
RN   [12]
RP   FUNCTION, INTERACTION WITH ODF2, AND SUBCELLULAR LOCATION.
RX   PubMed=23400999; DOI=10.1083/jcb.201206013;
RA   Kuhns S., Schmidt K.N., Reymann J., Gilbert D.F., Neuner A., Hub B.,
RA   Carvalho R., Wiedemann P., Zentgraf H., Erfle H., Klingmuller U.,
RA   Boutros M., Pereira G.;
RT   "The microtubule affinity regulating kinase MARK4 promotes axoneme
RT   extension during early ciliogenesis.";
RL   J. Cell Biol. 200:505-522(2013).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-543, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   FUNCTION, INTERACTION WITH MAPT, AND SUBCELLULAR LOCATION.
RX   PubMed=23666762; DOI=10.1007/s12017-013-8232-3;
RA   Gu G.J., Lund H., Wu D., Blokzijl A., Classon C., von Euler G.,
RA   Landegren U., Sunnemark D., Kamali-Moghaddam M.;
RT   "Role of individual MARK isoforms in phosphorylation of tau at Ser262 in
RT   Alzheimer's disease.";
RL   NeuroMolecular Med. 15:458-469(2013).
RN   [15]
RP   FUNCTION, DEVELOPMENTAL STAGE, AND PHOSPHORYLATION.
RX   PubMed=25123532; DOI=10.1016/j.ejcb.2014.07.004;
RA   Rovina D., Fontana L., Monti L., Novielli C., Panini N., Sirchia S.M.,
RA   Erba E., Magnani I., Larizza L.;
RT   "Microtubule-associated protein/microtubule affinity-regulating kinase 4
RT   (MARK4) plays a role in cell cycle progression and cytoskeletal dynamics.";
RL   Eur. J. Cell Biol. 93:355-365(2014).
RN   [16]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLN-377 AND CYS-418.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase (PubMed:15009667,
CC       PubMed:14594945, PubMed:23666762, PubMed:23184942). Phosphorylates the
CC       microtubule-associated protein MAPT/TAU (PubMed:14594945,
CC       PubMed:23666762). Also phosphorylates the microtubule-associated
CC       proteins MAP2 and MAP4 (PubMed:14594945). Involved in regulation of the
CC       microtubule network, causing reorganization of microtubules into
CC       bundles (PubMed:14594945, PubMed:25123532). Required for the initiation
CC       of axoneme extension during cilium assembly (PubMed:23400999).
CC       Regulates the centrosomal location of ODF2 and phosphorylates ODF2 in
CC       vitro (PubMed:23400999). Plays a role in cell cycle progression,
CC       specifically in the G1/S checkpoint (PubMed:25123532). Reduces neuronal
CC       cell survival (PubMed:15009667). Plays a role in energy homeostasis by
CC       regulating satiety and metabolic rate (By similarity). Promotes
CC       adipogenesis by activating JNK1 and inhibiting the p38MAPK pathway, and
CC       triggers apoptosis by activating the JNK1 pathway (By similarity).
CC       Phosphorylates mTORC1 complex member RPTOR and acts as a negative
CC       regulator of the mTORC1 complex, probably due to disruption of the
CC       interaction between phosphorylated RPTOR and the RRAGA/RRAGC
CC       heterodimer which is required for mTORC1 activation (PubMed:23184942).
CC       {ECO:0000250|UniProtKB:Q8CIP4, ECO:0000269|PubMed:14594945,
CC       ECO:0000269|PubMed:15009667, ECO:0000269|PubMed:23184942,
CC       ECO:0000269|PubMed:23400999, ECO:0000269|PubMed:23666762,
CC       ECO:0000269|PubMed:25123532}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:14594945, ECO:0000269|PubMed:15009667,
CC         ECO:0000269|PubMed:23184942};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:14594945,
CC         ECO:0000269|PubMed:15009667, ECO:0000269|PubMed:23184942};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:14594945};
CC   -!- ACTIVITY REGULATION: Activated by phosphorylation on Thr-214.
CC       {ECO:0000269|PubMed:14976552}.
CC   -!- SUBUNIT: Interacts with MAPT/TAU (PubMed:23666762). Interacts with
CC       gamma-tubulin (PubMed:14594945). Interacts with ODF2 (PubMed:23400999).
CC       Interacts with USP9X (PubMed:18254724). Interacts with YWHAQ
CC       (PubMed:16959763). {ECO:0000269|PubMed:14594945,
CC       ECO:0000269|PubMed:16959763, ECO:0000269|PubMed:18254724,
CC       ECO:0000269|PubMed:23400999, ECO:0000269|PubMed:23666762}.
CC   -!- INTERACTION:
CC       Q96L34; Q06481-5: APLP2; NbExp=3; IntAct=EBI-302319, EBI-25646567;
CC       Q96L34; P05067: APP; NbExp=3; IntAct=EBI-302319, EBI-77613;
CC       Q96L34; P60953: CDC42; NbExp=2; IntAct=EBI-302319, EBI-81752;
CC       Q96L34; P48730-2: CSNK1D; NbExp=3; IntAct=EBI-302319, EBI-9087876;
CC       Q96L34; Q15323: KRT31; NbExp=3; IntAct=EBI-302319, EBI-948001;
CC       Q96L34; P07948: LYN; NbExp=3; IntAct=EBI-302319, EBI-79452;
CC       Q96L34; Q9BYG4: PARD6G; NbExp=2; IntAct=EBI-302319, EBI-295417;
CC       Q96L34; Q8ND90: PNMA1; NbExp=2; IntAct=EBI-302319, EBI-302345;
CC       Q96L34; P41743: PRKCI; NbExp=2; IntAct=EBI-302319, EBI-286199;
CC       Q96L34; Q15831: STK11; NbExp=2; IntAct=EBI-302319, EBI-306838;
CC       Q96L34; P23258: TUBG1; NbExp=4; IntAct=EBI-302319, EBI-302589;
CC       Q96L34; Q04917: YWHAH; NbExp=6; IntAct=EBI-302319, EBI-306940;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing
CC       center, centrosome {ECO:0000269|PubMed:14594945}. Cytoplasm,
CC       cytoskeleton, microtubule organizing center
CC       {ECO:0000269|PubMed:14594945}. Cytoplasm, cytoskeleton, cilium basal
CC       body {ECO:0000269|PubMed:23400999}. Cytoplasm, cytoskeleton, cilium
CC       axoneme {ECO:0000269|PubMed:23400999}. Cytoplasm
CC       {ECO:0000269|PubMed:23400999, ECO:0000269|PubMed:23666762}. Cell
CC       projection, dendrite {ECO:0000269|PubMed:23666762}. Note=Localized at
CC       the tips of neurite-like processes in differentiated neuroblast cells.
CC       Detected in the cytoplasm and neuropil of the hippocampus.
CC       {ECO:0000269|PubMed:14594945, ECO:0000269|PubMed:23666762}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=MARK4L;
CC         IsoId=Q96L34-1; Sequence=Displayed;
CC       Name=2; Synonyms=MARKL1S, MARK4S;
CC         IsoId=Q96L34-2; Sequence=VSP_004946;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Isoform 2 is brain-specific
CC       (PubMed:11326310). Expressed at highest levels in brain and testis.
CC       Also expressed in heart, lung, liver, muscle, kidney and spleen
CC       (PubMed:14594945). {ECO:0000269|PubMed:11326310,
CC       ECO:0000269|PubMed:14594945}.
CC   -!- DEVELOPMENTAL STAGE: Expressed at all stages of the mitotic cell cycle.
CC       {ECO:0000269|PubMed:25123532}.
CC   -!- PTM: Ubiquitinated with 'Lys-29'- and 'Lys-33'-linked polyubiquitins
CC       which appear to impede LKB1-mediated phosphorylation. Deubiquitinated
CC       by USP9X. {ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:18254724}.
CC   -!- PTM: Phosphorylated at Thr-214 by STK11/LKB1 in complex with STE20-
CC       related adapter-alpha (STRADA) pseudo kinase and CAB39
CC       (PubMed:14976552). Phosphorylated throughout the cell cycle
CC       (PubMed:25123532). {ECO:0000269|PubMed:14976552,
CC       ECO:0000269|PubMed:25123532}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr
CC       protein kinase family. SNF1 subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB47489.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAB55238.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MARK4ID419.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB049127; BAB39380.1; -; mRNA.
DR   EMBL; AB088047; BAC03375.1; -; mRNA.
DR   EMBL; AY057448; AAL23683.1; -; mRNA.
DR   EMBL; AX305105; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AX305106; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AY120867; AAM55491.1; -; mRNA.
DR   EMBL; AB058763; BAB47489.1; ALT_INIT; mRNA.
DR   EMBL; AK027619; BAB55238.1; ALT_INIT; mRNA.
DR   EMBL; AK075272; BAC11510.1; -; mRNA.
DR   CCDS; CCDS12658.1; -. [Q96L34-2]
DR   CCDS; CCDS56097.1; -. [Q96L34-1]
DR   RefSeq; NP_001186796.1; NM_001199867.1. [Q96L34-1]
DR   RefSeq; NP_113605.2; NM_031417.3. [Q96L34-2]
DR   PDB; 5ES1; X-ray; 2.80 A; A=44-370.
DR   PDBsum; 5ES1; -.
DR   AlphaFoldDB; Q96L34; -.
DR   SMR; Q96L34; -.
DR   BioGRID; 121760; 68.
DR   IntAct; Q96L34; 40.
DR   MINT; Q96L34; -.
DR   STRING; 9606.ENSP00000262891; -.
DR   BindingDB; Q96L34; -.
DR   ChEMBL; CHEMBL5754; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q96L34; -.
DR   GuidetoPHARMACOLOGY; 2100; -.
DR   GlyGen; Q96L34; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q96L34; -.
DR   PhosphoSitePlus; Q96L34; -.
DR   BioMuta; MARK4; -.
DR   DMDM; 29840797; -.
DR   EPD; Q96L34; -.
DR   jPOST; Q96L34; -.
DR   MassIVE; Q96L34; -.
DR   MaxQB; Q96L34; -.
DR   PaxDb; Q96L34; -.
DR   PeptideAtlas; Q96L34; -.
DR   PRIDE; Q96L34; -.
DR   ProteomicsDB; 77145; -. [Q96L34-1]
DR   ProteomicsDB; 77146; -. [Q96L34-2]
DR   Antibodypedia; 31285; 385 antibodies from 36 providers.
DR   DNASU; 57787; -.
DR   Ensembl; ENST00000262891.9; ENSP00000262891.3; ENSG00000007047.16. [Q96L34-1]
DR   Ensembl; ENST00000300843.8; ENSP00000300843.3; ENSG00000007047.16. [Q96L34-2]
DR   GeneID; 57787; -.
DR   KEGG; hsa:57787; -.
DR   MANE-Select; ENST00000262891.9; ENSP00000262891.3; NM_001199867.2; NP_001186796.1.
DR   UCSC; uc002pba.3; human. [Q96L34-1]
DR   CTD; 57787; -.
DR   DisGeNET; 57787; -.
DR   GeneCards; MARK4; -.
DR   HGNC; HGNC:13538; MARK4.
DR   HPA; ENSG00000007047; Low tissue specificity.
DR   MIM; 606495; gene.
DR   neXtProt; NX_Q96L34; -.
DR   OpenTargets; ENSG00000007047; -.
DR   PharmGKB; PA30641; -.
DR   VEuPathDB; HostDB:ENSG00000007047; -.
DR   eggNOG; KOG0586; Eukaryota.
DR   GeneTree; ENSGT00940000159555; -.
DR   HOGENOM; CLU_000288_157_5_1; -.
DR   InParanoid; Q96L34; -.
DR   OMA; CHLPWDK; -.
DR   OrthoDB; 1127668at2759; -.
DR   PhylomeDB; Q96L34; -.
DR   TreeFam; TF315213; -.
DR   PathwayCommons; Q96L34; -.
DR   Reactome; R-HSA-5620912; Anchoring of the basal body to the plasma membrane.
DR   SignaLink; Q96L34; -.
DR   SIGNOR; Q96L34; -.
DR   BioGRID-ORCS; 57787; 11 hits in 1108 CRISPR screens.
DR   ChiTaRS; MARK4; human.
DR   GeneWiki; MARK4; -.
DR   GenomeRNAi; 57787; -.
DR   Pharos; Q96L34; Tchem.
DR   PRO; PR:Q96L34; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; Q96L34; protein.
DR   Bgee; ENSG00000007047; Expressed in cortical plate and 198 other tissues.
DR   ExpressionAtlas; Q96L34; baseline and differential.
DR   Genevisible; Q96L34; HS.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0036064; C:ciliary basal body; IMP:CACAO.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0030425; C:dendrite; IDA:UniProtKB.
DR   GO; GO:0000930; C:gamma-tubulin complex; IDA:ARUK-UCL.
DR   GO; GO:0015630; C:microtubule cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0005815; C:microtubule organizing center; IDA:UniProtKB.
DR   GO; GO:0030496; C:midbody; IDA:ARUK-UCL.
DR   GO; GO:0043005; C:neuron projection; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; NAS:UniProtKB.
DR   GO; GO:0043015; F:gamma-tubulin binding; IDA:UniProtKB.
DR   GO; GO:0008017; F:microtubule binding; IDA:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0048156; F:tau protein binding; NAS:ARUK-UCL.
DR   GO; GO:0050321; F:tau-protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0043130; F:ubiquitin binding; NAS:UniProtKB.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0044782; P:cilium organization; IGI:ARUK-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0001578; P:microtubule bundle formation; IEP:UniProtKB.
DR   GO; GO:0000226; P:microtubule cytoskeleton organization; IMP:UniProtKB.
DR   GO; GO:0007399; P:nervous system development; IDA:UniProtKB.
DR   GO; GO:0045787; P:positive regulation of cell cycle; IDA:ARUK-UCL.
DR   GO; GO:0045724; P:positive regulation of cilium assembly; IMP:ARUK-UCL.
DR   GO; GO:0043068; P:positive regulation of programmed cell death; NAS:UniProtKB.
DR   GO; GO:1904781; P:positive regulation of protein localization to centrosome; IMP:ARUK-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:0046605; P:regulation of centrosome cycle; IMP:ARUK-UCL.
DR   InterPro; IPR028375; KA1/Ssp2_C.
DR   InterPro; IPR001772; KA1_dom.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR015940; UBA.
DR   Pfam; PF02149; KA1; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00627; UBA; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SMART; SM00165; UBA; 1.
DR   SUPFAM; SSF103243; SSF103243; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50032; KA1; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS50030; UBA; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell cycle; Cell division;
KW   Cell projection; Cilium biogenesis/degradation; Cytoplasm; Cytoskeleton;
KW   Kinase; Mitosis; Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Ubl conjugation.
FT   CHAIN           1..752
FT                   /note="MAP/microtubule affinity-regulating kinase 4"
FT                   /id="PRO_0000086307"
FT   DOMAIN          59..310
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          324..368
FT                   /note="UBA"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00212"
FT   DOMAIN          703..752
FT                   /note="KA1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00565"
FT   REGION          1..36
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          385..614
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        390..413
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        441..455
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        459..480
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        494..511
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        527..552
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        181
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         65..73
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         88
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         214
FT                   /note="Phosphothreonine; by LKB1"
FT                   /evidence="ECO:0000269|PubMed:14976552"
FT   MOD_RES         423
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8CIP4"
FT   MOD_RES         543
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         628..752
FT                   /note="ADEPERIGGPEVTSCHLPWDQTETAPRLLRFPWSVKLTSSRPPEALMAALRQ
FT                   ATAAARCRCRQPQPFLLACLHGGAGGPEPLSHFEVEVCQLPRPGLRGVLFRRVAGTALA
FT                   FRTLVTRISNDLEL -> TLDPSKRQNSNRCVSGASLPQGSKIRSQTNLRESGDLRSQV
FT                   AIYLGIKRKPPPGCSDSPGV (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11326310,
FT                   ECO:0000303|PubMed:11347906"
FT                   /id="VSP_004946"
FT   VARIANT         377
FT                   /note="R -> Q (in dbSNP:rs35070611)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040766"
FT   VARIANT         418
FT                   /note="R -> C (in a colorectal adenocarcinoma sample;
FT                   somatic mutation; dbSNP:rs780763668)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040767"
FT   MUTAGEN         214
FT                   /note="T->A: Prevents phosphorylation and activation by
FT                   STK11/LKB1 complex."
FT                   /evidence="ECO:0000269|PubMed:14976552"
FT   MUTAGEN         214
FT                   /note="T->E: Mimicks phosphorylation state, leading to
FT                   increased activity. Decreases mTORC1 activity."
FT                   /evidence="ECO:0000269|PubMed:14976552,
FT                   ECO:0000269|PubMed:23184942"
FT   CONFLICT        70
FT                   /note="F -> S (in Ref. 1; BAB39380/BAC03375)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        518
FT                   /note="P -> L (in Ref. 6; BAB55238)"
FT                   /evidence="ECO:0000305"
FT   STRAND          59..67
FT                   /evidence="ECO:0007829|PDB:5ES1"
FT   STRAND          69..78
FT                   /evidence="ECO:0007829|PDB:5ES1"
FT   TURN            79..81
FT                   /evidence="ECO:0007829|PDB:5ES1"
FT   STRAND          84..91
FT                   /evidence="ECO:0007829|PDB:5ES1"
FT   HELIX           92..94
FT                   /evidence="ECO:0007829|PDB:5ES1"
FT   HELIX           97..111
FT                   /evidence="ECO:0007829|PDB:5ES1"
FT   STRAND          121..126
FT                   /evidence="ECO:0007829|PDB:5ES1"
FT   STRAND          128..135
FT                   /evidence="ECO:0007829|PDB:5ES1"
FT   HELIX           143..150
FT                   /evidence="ECO:0007829|PDB:5ES1"
FT   HELIX           155..174
FT                   /evidence="ECO:0007829|PDB:5ES1"
FT   STRAND          186..189
FT                   /evidence="ECO:0007829|PDB:5ES1"
FT   STRAND          195..197
FT                   /evidence="ECO:0007829|PDB:5ES1"
FT   TURN            219..221
FT                   /evidence="ECO:0007829|PDB:5ES1"
FT   HELIX           224..228
FT                   /evidence="ECO:0007829|PDB:5ES1"
FT   HELIX           235..251
FT                   /evidence="ECO:0007829|PDB:5ES1"
FT   HELIX           261..270
FT                   /evidence="ECO:0007829|PDB:5ES1"
FT   HELIX           281..290
FT                   /evidence="ECO:0007829|PDB:5ES1"
FT   TURN            295..297
FT                   /evidence="ECO:0007829|PDB:5ES1"
FT   HELIX           301..304
FT                   /evidence="ECO:0007829|PDB:5ES1"
FT   HELIX           308..311
FT                   /evidence="ECO:0007829|PDB:5ES1"
FT   HELIX           332..339
FT                   /evidence="ECO:0007829|PDB:5ES1"
FT   TURN            340..342
FT                   /evidence="ECO:0007829|PDB:5ES1"
FT   HELIX           345..352
FT                   /evidence="ECO:0007829|PDB:5ES1"
FT   TURN            353..355
FT                   /evidence="ECO:0007829|PDB:5ES1"
FT   HELIX           359..366
FT                   /evidence="ECO:0007829|PDB:5ES1"
FT   TURN            367..369
FT                   /evidence="ECO:0007829|PDB:5ES1"
SQ   SEQUENCE   752 AA;  82520 MW;  4B430FFD2B150E7A CRC64;
     MSSRTVLAPG NDRNSDTHGT LGSGRSSDKG PSWSSRSLGA RCRNSIASCP EEQPHVGNYR
     LLRTIGKGNF AKVKLARHIL TGREVAIKII DKTQLNPSSL QKLFREVRIM KGLNHPNIVK
     LFEVIETEKT LYLVMEYASA GEVFDYLVSH GRMKEKEARA KFRQIVSAVH YCHQKNIVHR
     DLKAENLLLD AEANIKIADF GFSNEFTLGS KLDTFCGSPP YAAPELFQGK KYDGPEVDIW
     SLGVILYTLV SGSLPFDGHN LKELRERVLR GKYRVPFYMS TDCESILRRF LVLNPAKRCT
     LEQIMKDKWI NIGYEGEELK PYTEPEEDFG DTKRIEVMVG MGYTREEIKE SLTSQKYNEV
     TATYLLLGRK TEEGGDRGAP GLALARVRAP SDTTNGTSSS KGTSHSKGQR SSSSTYHRQR
     RHSDFCGPSP APLHPKRSPT STGEAELKEE RLPGRKASCS TAGSGSRGLP PSSPMVSSAH
     NPNKAEIPER RKDSTSTPNN LPPSMMTRRN TYVCTERPGA ERPSLLPNGK ENSSGTPRVP
     PASPSSHSLA PPSGERSRLA RGSTIRSTFH GGQVRDRRAG GGGGGGVQNG PPASPTLAHE
     AAPLPAGRPR PTTNLFTKLT SKLTRRVADE PERIGGPEVT SCHLPWDQTE TAPRLLRFPW
     SVKLTSSRPP EALMAALRQA TAAARCRCRQ PQPFLLACLH GGAGGPEPLS HFEVEVCQLP
     RPGLRGVLFR RVAGTALAFR TLVTRISNDL EL
//
